In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The most recent results from the trial will be presented today at the 60th American… Read More »
SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May… Read More »
Jen BabakhanNov 29 Imagine Florida being too cool: That’s the case for this woman with a rare condition called cold agglutinin disorder. When the temperature dips below 75 degrees, her body turns on itself. Courtesy Bioverativ Sometimes you wake up more tired than usual. Sometimes the weight seems to pile on for no reason. But… Read More »
Shoulder injuries don’t discriminate. They account for up to 36% of all major weight-room injuries (that is, the ones severe enough to require medical attention), and they target big and small guys equally. Morey Kolber, Ph.D., C.S.C.S., was one of those casualties. “I separated one shoulder and partially tore the rotator cuff on the other… Read More »
Print this page SATURDAY, Dec. 1, 2018 — Teens and adults with epilepsy are at increased risk for depression and should undergo regular screening, two new studies say. In one study, researchers evaluated nearly 400 teens, ages 15 to 18, with epilepsy. They found that 8 percent had moderate or severe depression and another 5… Read More »